Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer
Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations [Yahoo! Finance]
PIRS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pieris Pharmaceuticals, Inc. Is Fair to Shareholders
Pieris Pharmaceuticals Second Quarter 2024 Earnings: US$2.76 loss per share (vs US$3.63 profit in 2Q 2023) [Yahoo! Finance]
We're A Little Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate [Yahoo! Finance]